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Background: We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer.
We hypothesised that inhibiting p-S6K signalling with the dual m-TORC1/2 inhibitor in patients receiving weekly paclitaxel
could improve outcomes in such patients.
Patients and methods: In dose escalation, weekly paclitaxel (80mg/m2) was given 6/7weeks in combination with two
intermittent schedules of vistusertib (dosing starting on the day of paclitaxel): schedule A, vistusertib dosed bd for 3 consecutive
days per week (3/7 days) and schedule B, vistusertib dosed bd for 2 consecutive days per week (2/7 days). After establishing a
recommended phase II dose (RP2D), expansion cohorts in high-grade serous ovarian cancer (HGSOC) and squamous non-small-
cell lung cancer (sqNSCLC) were explored in 25 and 40 patients, respectively.
Results: The dose-escalation arms comprised 22 patients with advanced solid tumours. The dose-limiting toxicities
were fatigue and mucositis in schedule A and rash in schedule B. On the basis of toxicity and pharmacokinetic (PK) and
pharmacodynamic (PD) evaluations, the RP2D was established as 80mg/m2 paclitaxel with 50mg vistusertib bd 3/7 days for 6/
7weeks. In the HGSOC expansion, RECIST and GCIG CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively, with
median progression-free survival (mPFS) of 5.8months (95% CI: 3.28–18.54). The RP2D was not well tolerated in the SqNSCLC
expansion, but toxicities were manageable after the daily vistusertib dose was reduced to 25mg bd for the following 23
patients. The RECIST response rate in this group was 8/23 (35%), and the mPFS was 5.8months (95% CI: 2.76–21.25).
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Discussion: In this phase I trial, we report a highly active and well-tolerated combination of vistusertib, administered as an
intermittent schedule with weekly paclitaxel, in patients with HGSOC and SqNSCLC.
Clinical trial registration: ClinicialTrials.gov identifier: CNCT02193633
Key words: phase 1, m-TORC1/m-TORC2 inhibitor, combination therapy, ovarian cancer, squamous non-small-cell lung
cancer
Introduction
We have previously studied cancer cells isolated from serous
effusions and shown raised p-S6K to be associated with chemo-
resistance and poor clinical outcome in ovarian and lung can-
cers, respectively [1, 2]. This led us to hypothesise that
inhibition of m-TOR signalling, in combination with chemo-
therapy, could improve treatment outcomes in these tumour
types.
Analogues of rapamycin such as everolimus have been recog-
nised to inhibit only m-TORC1 and not m-TORC2 in the m-
TOR complex [3]. The dual m-TORC1/2 inhibitor vistusertib
(AZD2014) has a short half-life, giving greater flexibility for
intermittent dosing schedules [4, 5]. Weekly paclitaxel was
chosen as the chemotherapy backbone, as it is often used to treat
advanced ovarian cancer. Pre-clinical studies of vistusertib and
paclitaxel revealed an additive effect on growth in vitro and
in vivo, with the combination showing increased apoptosis and
metabolic effects consistent with the mechanism of action of vis-
tusertib [6].
Here, we report the results of the TAX-TORC study, a phase IB
dose-escalation study, with a pre-planned dose-expansion cohort
in HGSOC and an additional expansion cohort in sqNSCLC
(supplementary Figure S1, available at Annals of Oncology
online).
Patients and methods
Conduct of the study
The academic sponsors of this study were The Institute of Cancer
Research and The Royal Marsden (CCR3667), and the trial was reviewed
by a central research ethics committee (REC ref: 13/LO/0066). The study
was funded by AstraZeneca. Nine Experimental Cancer Medicine
Centres across the UK participated in this study. All patients were treated
after obtaining written, informed consent. Cancer Research UK trial
number: CRUKD/12/013.
Inclusion/exclusion criteria: Inclusion criteria in the dose-escalation
arm included an ECOG performance status of 0 or 1. Haematological
and biochemistry criteria were standard for phase I studies, and details
are available in the supplementary data, available at Annals of Oncology
online.
Treatment
The dose of paclitaxel administered was 80mg/m2 once weekly for 6/7
weeks in a 7-week cycle. In the first week of the dose-escalation cohorts,
patients received only paclitaxel on C1D1, then vistusertib on C1D3 to
allow for PK and PD samplings. Patients then received weekly paclitaxel
(on days 8, 15, 22, 29, and 36) with vistusertib, also starting on days 8, 15,
22, 29, and 36, given orally twice daily either for three consecutive days
per week (schedule A: 3/7 days, 6/7 weeks) or two consecutive days per
week (schedule B: 2/7 days, 6/7 weeks). In the dose expansion, schedule A
was taken forward with patients dosing with vistusertib weekly on days
1–3 for 6weeks of a 7-week cycle.
Evaluation of toxicity
NCI-CTCAE V40 was used to assess toxicity.
Evaluation of response
RECIST v1.1 was used to assess tumour response supported by GCIG
CA125 response in patients with HGSOC. Response was assessed at the
end of every 7-week cycle.
Pharmacokinetic and pharmacodynamic
evaluations
Pharmacokinetic (PK) sampling was carried out for all patients in
the dose-escalation arm for 24 h on C1D1 (paclitaxel alone), C1D3
(vistusertib alone), and on C1D1 (combination of paclitaxel and
vistusertib). PD sampling was carried out for all patients in the dose-
escalation arm. Sampling for PD assays was carried out on
the same days as PK sampling. Phosphorylation of AKTSer473 (Ser473
p-AKT) was quantified in platelet-rich plasma (PRP) (for
detailed methods, see supplementary data, available at Annals of
Oncology online) [7].
Sequencing
DNA was extracted from formalin-fixed and paraffin-embedded (FFPE)
tumour blocks. In addition, circulating free DNA (cfDNA) when col-
lected at baseline, at the end of cycle 1 and, where possible, at progression,
was extracted from 4 to 8mL of plasma. Sequencing libraries were con-
structed using a customised Generead DNAseq Mix-n-Match v2 panel
(Qiagen) covering 4841 amplicons (310, 077 bp) across 67 genes.
Libraries were run using theMiSeq Sequencer (Illumina); sequence align-
ment andmutation calling were performed.
Methods—statistical analysis
The data cut-off for this article was 1 October 2017. Demographics were
analysed by descriptive statistics. Safety was assessed in all enrolled
patients. Patients considered not assessable for response had no post-
baseline CT scan. The number of patients required for the dose-
escalation phase was dependent on toxicities observed as the trial pro-
gressed. No formal power calculations were done.
Progression-free survival was estimated by the Kaplan–Meier
method, beginning on the day of the first dose (C1D1) and continuing
until disease progression. Patients who came off study for
reasons other than disease progression (clinical or RECIST) were
censored. This study is registered with ClinicalTrials.gov, identifier:
NCT02193633.
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Results
Dose-escalation cohort
Toxicity. Twenty-two patients were recruited to the dose-
escalation cohort. The most common tumours were ovarian and
lung cancers (supplementary Table S1, available at Annals of
Oncology online). In the dose-escalation phase, vistusertib was
tested at 25mg, 50mg, and 75mg bd 3/7 days, 6/7 weeks (sched-
ule A) with no dose limiting toxicities (DLTs) in the 25mg or
50mg groups. Two of the three patients in the 75mg group expe-
rienced DLTs of fatigue and mucositis. Vistusertib was then
tested at 50mg and 75mg bd 2/7 days (schedule B) with no DLTs.
However, two of the three patients taking 100mg bd 2/7 days
experienced DLTs of rash (supplementary Figure S2, available at
Annals of Oncology online). The maximally tolerated dose (MTD)
of schedule A was, thus, 80mg/m2 weekly paclitaxel with 50mg
vistusertib bd 3/7 days for 6/7 weeks in a 7-week cycle, with dos-
ing starting concurrently on day 1 of each week. The MTD of
schedule B was 80mg/m2 weekly paclitaxel with 75mg vistusertib
bd 2/7 days for 6/7 weeks in a 7-week cycle, with dosing starting
concurrently on day 1 of each week. The most common toxicities
across both schedules were predominantly grade 1–2 fatigue,
nausea, anaemia, and diarrhoea (Table 1), which are similar to
that seen with weekly paclitaxel administration.
Pharmacokinetics. In all schedules tested, the PK of paclitaxel
when administered alone or in combination with vistusertib was
similar (Table 2). The PK of vistusertib alone or vistusertib in
combination with paclitaxel in both schedules was comparable
with previous single agent studies [5] (data not shown). The areas
under the curve (AUC) versus dose of vistusertib was approxi-
mately dose proportional (supplementary Figure S3, available at
Annals of Oncology online). Altogether, these suggest that there is
no drug-drug PK interaction on drug exposure for either pacli-
taxel or vistusertib in combination compared with either agent
administered alone.
Pharmacodynamics. At the recommended phase II dose (RP2D)
level of 50mg bd of vistusertib and 80mg/m2 of paclitaxel, there
was a statistically non-significant increase in levels of Ser473
p-AKT at 4 h following 80mg/m2 paclitaxel (1.4 fold; P¼ 0.14).
Vistusertib (50mg bd 3/7) in addition to paclitaxel produced a
reduction in Ser473 p-AKT at 4 h post-vistusertib to 53% of pre-
dose levels (P¼ 0.0495). This was 62% lower than the corre-
sponding time-point following paclitaxel alone, suggesting that,
at the RP2D of the combination, there is a significant reduction
in p-AKT levels in normal tissue compared with baseline
(Figure 1).
RP2D. In combination with weekly paclitaxel administered
at 80mg/m2 once weekly, the MTD of vistusertib was 50mg bd
(3/7 days) (schedule A) or 75mg bd (2/7 days) (schedule B). Both
doses had acceptable PK and PD profiles and would be acceptable
as per the pharmacological audit trail [8]. Weekly vistusertib
50mg bd 3 days on/4 days off combined with weekly paclitaxel
Table 1. Toxicity in the dose-escalation arm
Adverse event Escalation 3d on, 4d off Escalation 2d on, 5d off Total
(N5 21)





















Fatigue 3 0 5 0 0 3 1 2 1 1 16
Nausea 3 0 4 0 0 0 4 0 2 0 13
Anaemia 2 0 4 0 2 0 2 0 2 0 12
Diarrhoea 1 0 3 1 1 1 3 0 1 0 11
Peripheral sensory
neuropathy
1 0 2 0 1 0 3 0 2 0 9
Skin rash 1 0 1 0 1 0 3 0 1 2 9
Alopecia 1 0 4 0 2 0 1 0 0 0 8
Dysgeusia 0 0 3 0 1 0 4 0 0 0 8
Mucositis 1 0 2 0 1 1 1 0 1 0 7
Neutropenia 0 0 2 1 1 2 0 0 1 0 7
Dyspepsia/gastric reﬂux 1 0 1 0 0 0 1 0 2 0 5
Hypophosphataemia 1 0 1 0 0 3 0 0 0 0 5
Pain 0 0 1 0 1 0 1 0 1 0 4
Paronychia 0 0 3 0 0 0 1 0 1 0 5
All drug-related events (possibly, probably and, deﬁnitely related) seen in more than 20% of patients in the dose-escalation cohorts. A total of 22 patients
were treated in the dose escalation. One patient was treated with vistusertib on schedule B at 50mg instead of 100mg owing to urgent reporting of two
dose-limiting toxicities. The patient did not have grade 3 or 4 toxicity or a dose-limiting toxicity, was evaluable, but has not been represented in the table
for simplicity.
Original article Annals of Oncology
1920 | Basu et al. Volume 29 | Issue 9 | 2018
80mg/m2 was taken forward as the RP2D based on reduced oc-
currence of grade 3 fatigue in this cohort.
Ovarian cancer expansion. Twenty-seven patients with relapsed/re-
fractoryHGSOCwere treated at the RP2D. Twopatients were replaced
as per protocol and were not considered for assessment of response.
The median number of previous treatments was three: the majority
(26/27; 96%) of patients having received paclitaxel and 3/27 patients
(11%) having previously received weekly paclitaxel (supplementary
Table S2, available at Annals of Oncology online). The RECIST and
CA125 response rates were 13/25 (52%) and 16/25 (64%), respectively
(Figure 2A). ThemPFSwas 58months (95%CI: 3.3–18.5).
DNA sequencing (targeted panel of 67 genes) of FFPE tissue
revealed that the most common mutation was TP53 detected in
23/25 (92%) patients. There was no correlation between specific
mutations and response (Figure 2B).
Squamous lung cancer expansion. Following two partial
responses in patients with sqNSCLC in the dose-escalation co-
hort, we conducted a dose expansion in a cohort of 40 patients,
starting at the RP2D of 80mg/m2 paclitaxel and 50mg vistusertib
Table 2. Pharmacokinetic proﬁle of vistusertib
Variable Day AZD2014/paclitaxel
25 mg/80 mg 50 mg/80 mg 75 mg/80 mg 100 mg/80 mg
Geometric mean N Geometric mean N Geometric mean N Geometric mean N
AUClast (h*ng/mL) 3 2090 (1290–3462) 3 2602 (708–11486) 7 7543 (4192–16542) 9 7556 (4188–12884) 3
8 1054 (181–2785) 3 2026 (800–6137) 7 5209 (1576–13363) 8 7347 (4875–13997) 3
Cmax (ng/mL) 3 579 (478–785) 3 840 (462–3580) 7 1840 (983–2870) 9 1960 (1180–2670) 3
8 248 (80–507) 3 500 (244–764) 7 1122 (442–1920) 8 1830 (1490–2420) 3
HL Lambda_z (h) 3 3.3 (2.3–4.2) 3 1.8 (0.8–3.2) 6 2.7 (1.2–5.9) 8 3.0 (2.5–3.3) 3
8 3.5 (1.9–6.1) 3 2.2 (1.7–2.9) 6 3.1 (1.7–9.7) 8 2.8 (1.2–5.3) 3
The area under the curve (AUC), maximal concentration (Cmax), and half-life (HL) of vistusertib on C1D3 (administered as a single agent) and C1D8
(administered in combination with paclitaxel) across the different dose levels in the dose-escalation cohort.
Figure 1. Pharmacodynamic proﬁle of vistusertib at 50mg bd 3/7. Phosphorylation of AKT (Ser473) in platelet-rich plasma was quantiﬁed
using MSD electrochemiluminescent immunoassays and normalised to corresponding total AKT values. Baseline values were established
prior to the start of treatment. On C1D1, only paclitaxel (80 mg/m2) was administered and a non-signiﬁcant rise in p-ATK at 4 h following
treatment was noted. On C1D4, a single dose of vistusertib was administered and non-signiﬁcant reduction of p-AKT was seen. On C1D8, the
combination of paclitaxel and vistusertib was administered, which caused a signiﬁcant reduction of p-AKT compared with baseline. Points
represent individual patients, orange line represents mean of up to N ¼ 6 patients. Four samples were excluded because of haemolysis,
which interfered with the assay (*P<0.05; paired t-test).
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Figure 2. Clinical outcomes of patients in the ovarian cancer expansion treated at the R2PD for ovarian cancer. (A) Waterfall plot of 23/25
patients with ovarian cancer treated at the RP2D for ovarian cancer that were evaluable for response; two patients clinically progressed with
bowel obstruction in the ﬁrst cycle and did not have a repeat CT scan to assess response. A total of 19 of 25 (76%) patients showed a reduc-
tion in size of their tumour, with 13/25 (52%) achieving a partial response. (B) Mutations in tumour tissue or plasma of patients compared
with clinical response. (C) Spider plots representing percentage change in measured sum of tumour dimensions of individual patients over
time (each cycle is 7 weeks).
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Figure 3. Clinical outcomes of patients in the squamous NSCLC expansion treated at the R2PD for squamous NSCLC. (A) Waterfall plot of
21/23 patients with sqNSCLC treated at RP2D of the combination; two patients clinically progressed within their ﬁrst cycle and repeat radio-
logical evaluation was not done. Eighteen of the 23 (78%) patients showed reduction in the size of their tumour with 8/23 (35%) achieving a
partial response. (B) Mutations in tumour tissue or plasma of patients compared with clinical response. (C) Spider plots representing percent-
age change in measured sum of tumour dimensions of individual patients over the time (each cycle is 7 weeks).
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bd 3/7 days. This schedule was poorly tolerated, with fatigue,
diarrhoea, and pneumonia being seen more frequently than in
the dose-escalation cohort (supplementary Table S3A, available
at Annals of Oncology online). The safety review committee
reviewed the data of the first 17 patients and decided to reduce
the dose of vistusertib to 25mg bd 3/7 days for the remaining 23
patients due to be treated in this cohort. This dose was known to
be pharmacodynamically active [5] and was better tolerated (sup-
plementary Table S3B, available at Annals of Oncology online).
The RECIST response rate in patients with sqNSCLC in the
25mg cohort was 8/23 (35%) (Figure 3A), with an mPFS of
5.8months (95% CI 2.8–21.3). Two patients with PIK3CAmuta-
tions showed partial responses, but there were no clear patterns
linking mutations to response (Figure 3B).
Discussion
We report the first study of the combination of weekly paclitaxel
with the dual m-TORC1/2 inhibitor, vistusertib, establishing a
safe dose and schedule and preliminary evidence of efficacy in
HGSOC and SqNSCLC. We chose to investigate the m-TORC1/2
inhibitor in the context of weekly paclitaxel, as this regimen is
often used in the setting of platinum-resistant ovarian cancer [9],
and taxanes are commonly used in the treatment of platinum-
resistant NSCLC (with comparable efficacy between weekly pacli-
taxel and docetaxel and better tolerability profile) [10, 11].
Toxicities of fatigue, nausea, anaemia, and diarrhoea in this
dose-escalation cohort were not dissimilar to previous studies
combining m-TOR inhibitors such as everolimus [12], ridaforo-
limus [13], or the m-TORC1/2 inhibitor, MLN028 [14], with
weekly paclitaxel regimens. Hyperglycaemia, which has been
commonly reported with m-TOR inhibitors, occurred at a very
low incidence in our study [all grades: N¼ 8 (11%), grade 3/4:
N¼ 1(1%)]. It was noted that many earlier studies were in breast
cancer, where weekly paclitaxel is often used as standard-of-care.
Of interest, in our study, patients with heavily pre-treated
HGSOC tolerated vistusertib at 50mg bd 3 days per week in com-
bination with weekly paclitaxel. However, patients with
sqNSCLC needed a dose reduction of vistusertib to 25mg bd
3 days per week. Patients with sqNSCLC often exhibit risk factors
and co-morbidities that correlate with poor tolerance of chemo-
therapy such as hypoxia, a history of smoking, and pulmonary fi-
brosis [15]. We have previously reported on the increased risk of
infections of patients treated with PI3K pathway inhibitors used
as part of combination therapy [16]. In our experience, this is the
first time that it has been necessary to recommend two separate
doses for different tumour types within the same study.
The PK profile of vistusertib was not significantly different
from previous reports in single-agent studies [5] and was no dif-
ferent when administered alone or in combination with pacli-
taxel. The pharmacodynamic profile of vistusertib in PRP
showed administration of vistusertib led to abrogation of
AKTSer473 phosphorylation, providing proof-of-principle of the
desired biological effect of inhibiting the PI3K–Akt-m-TOR
pathway.
The clinical outcomes of patients receiving the combination of
weekly paclitaxel and vistusertib in this non-randomised phase I
expansion were encouraging for the patient groups explored. In
the ovarian cohort, the three median lines of previous treatment
were: 12% of patients were platinum-refractory, 48% had pro-
gressed within 6months of the last platinum treatment, and 96%
had progressed within a year of their last platinum treatment. In
this cohort, the RECIST and CA125 response rates were 52% and
64%, respectively, with a progression-free interval of 5.8months,
which is better than historic data reported for the use of weekly
paclitaxel therapy [9]. The control chemotherapy arm of a con-
temporary phase III study studying the addition of bevacizumab
to chemotherapy in the setting of 2nd or 3rd line chemotherapy in
a platinum-resistant disease state achieved a response rate of 12%
and progression-free survival was 3.9months [17]. The results of
the TAX-TORC study have led to a randomised phase II study of
weekly paclitaxel versus paclitaxel and vistusertib, which is on-
going (ISRCTN16426935) [18].
The standard-of-care of sqNSCLC changed with the introduc-
tion of immune checkpoint inhibitors with response rates of
15% in patient cohorts not selected for PD-L1 expression con-
firmed by randomised control trials [19]. In the TAX-TORC
study, at the tolerated doses of paclitaxel (80mg/m2/week) and
vistusertib (25mg bd 3/7 days), the response rate and
progression-free survival was 35% and 5.8months, respectively.
These data exceed traditional outcomes for the sqNSCLC popula-
tion beyond first-line therapy and demonstrate potential for
benefit and warrant further evaluation. A possible use of this regi-
men could be in the setting of patients with sqNSCLC who do not
have expression of PD-L1 [20].
We attempted to identify biomarkers of response to the com-
bination by studying a panel of 67 genes that were known to be
commonly mutated in HGSOC [21] and sqNSCLC [22]. The
mutations found in our study were in keeping with those
described elsewhere in these tumour types; however, there were
no significant differences in mutation profiles of responders and
non-responders in this small dataset.
Conclusion
We report a phase I study combining weekly paclitaxel and a dual
m-TORC1/2 inhibitor, vistusertib, with expansions in HGSOC
and squamous NSCLC, which are both areas of unmet need. The
trial showed tolerable schedules in expansion cohorts of over 20
patients. The response rates and progression-free survival in these
non-randomised phase I expansions show promise, and rando-
mised phase II studies are recommended to study these combina-
tions further.
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